Pure Global
NCT06415526

OPERA - Incorporating Robotic Surgery in Both Mastectomy and DIEP Flap Reconstruction

Oncoplastic Entirely Robot-Assisted Approach (OPERA) - Incorporating Robotic Surgery in Both Mastectomy and DIEP Flap Reconstruction
Chang Gung Memorial Hospital·ClinicalTrials.gov·procedureCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Breast Cancer,Mastectomy; Lymphedema
Drug/Device/Intervention
OPERA
Study type
Observational
Intervention type
procedure
Sponsor & location
Primary sponsor
Chang Gung Memorial Hospital
Location
Taoyuan, Taiwan
Timeline & enrollment
Phase
N/A
Start date
May 03, 2024
End date
May 10, 2024
Enrollment
14 participants
Primary outcome

ARS incision,Robotic time,Flap size

Summary

Current breast cancer surgery is achieving minimally invasive approach to reduce incision
 while providing better surgical vision and freedom in mastectomy. Breast reconstruction with
 free deep inferior epigastric artery perforator (DIEP) flap was considered the gold standard,
 however, the donor site morbidity remains an endless concern. Here we applied
 robotic-assisted surgery in both mastectomy and free DIEP flap harvest, so-called Oncoplastic
 Entirely Robot-Assisted Approach (OPERA).
 
 A retrospective chart review identified 14 patients with unilateral breast cancer received
 robotic-assisted mastectomy and robotic assisted free DIEP flap harvest for breast
 reconstruction. The patient demographics and mastectomy and flap characteristics were
 reviewed.

ICD-10 classifications
Malignant mast cell tumourSecondary and unspecified malignant neoplasm of lymph nodesLymphoedema, not elsewhere classifiedBenign neoplasm: Lymph nodesMast cell leukaemia
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06415526
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06415526 through Pure Global AI's free database. This phase not specified trial is sponsored by Chang Gung Memorial Hospital and is currently Completed. The study focuses on Breast Cancer,Mastectomy; Lymphedema. Target enrollment is 14 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.